Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 15/20 | 0.47 |
| ▸ | SLC6A3 | Q01959 | 12/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 11/20 | 0.47 |
| ▸ | MEN1 | O00255 | 2/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP3A5 | P20815 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3972164 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3971604 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3980411 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3970062 | 1.00 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3972629 | 0.99 | MEN1 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3972647 | 0.97 | MEN1 (0.47) | SLC6A2SLC6A3SLC6A4MEN1KMT2A | |
| SCHEMBL3960521 | 0.90 | MEN1 (0.45) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL3950407 | 0.88 | STS (0.45) | MEN1KMT2ASTSCYP3A4CYP3A5 | |
| SCHEMBL3980468 | 0.88 | MEN1 (0.40) | MEN1KMT2A | |
| SCHEMBL3976438 | 0.88 | SLC6A2 (0.47) | SLC6A2MEN1KMT2ACYP3A4CYP3A5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2009-09-10 | — | — | US | disclosed |
| US-7550485-B2 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7550456-B2 | Substituted aryl cycloalkanoyl derivatives and methods of their use | WYETH (US) | 2009-06-23 | — | — | US | disclosed |
| US-7531543-B2 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2009-05-12 | — | — | US | disclosed |
| US-7524846-B2 | Arylalkyl- and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2009-04-28 | — | — | US | disclosed |
| US-7491723-B2 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2009-02-17 | — | — | US | disclosed |
| US-7419980-B2 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2008-09-02 | — | — | US | disclosed |
| US-7402698-B2 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2008-06-26 | — | — | US | disclosed |
| US-7365076-B2 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2008-04-29 | — | — | US | disclosed |
| EP-1687288-B1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH CORP (US) | 2008-01-16 | — | — | EP | disclosed |
| EP-1673358-A1 | PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | Wyeth (US) | 2006-06-28 | — | — | EP | disclosed |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-10-20 | — | — | US | disclosed |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | WYETH (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | WYETH (US) | 2005-08-25 | — | — | US | disclosed |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | WYETH (US) | 2005-08-04 | — | — | US | disclosed |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | WYETH (US) | 2005-07-07 | — | — | US | disclosed |
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | WYETH (US) | 2005-06-30 | — | — | US | disclosed |
| WO-2005037808-A1 | PHENYLPIPERAZINE CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | WYETH (US) | 2005-04-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050143579-A1 | Substituted aryl cycloalkanol derivatives and methods of their use | HTR3A, MAOA, FAAH | SLC6A2 125/4885SLC6A3 113/4885SLC6A4 72/4885 |
| US-20050148595-A1 | Arylalkyl-and cycloalkylalkyl-piperazine derivatives and methods of their use | GLS, HTR5A, HTR3A | SLC6A2 108/4885SLC6A3 80/4885SLC6A4 31/4885 |
| US-20080153826-A1 | SUBSTITUTED ARYL CYCLOALKANOL DERIVATIVES AND METHODS OF THEIR USE | HTR3A, MAOA, GLS | SLC6A2 53/4885SLC6A3 49/4885SLC6A4 38/4885 |
| US-20050171115-A1 | Alkanol and cycloalkanol-amine derivatives and methods of their use | FAAH, HTR3A, MAOA | SLC6A2 115/4885SLC6A3 149/4885SLC6A4 82/4885 |
| US-20090227585-A1 | SUBSTITUTED N-HETEROCYCLE DERIVATIVES AND METHODS OF THEIR USE | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A3 116/4885SLC6A4 44/4885 |
| US-20050234058-A1 | Secondary amino-and cycloamino-cycloalkanol derivatives and methods of their use | ASNS, GLS, GYS1 | SLC6A2 146/4885SLC6A3 160/4885SLC6A4 131/4885 |
| US-20050187251-A1 | Substituted N-heterocycle derivatives and methods of their use | MAOA, MAOB, SDHA | SLC6A2 71/4885SLC6A3 116/4885SLC6A4 44/4885 |
| US-20050192283-A1 | Fused-aryl and heteroaryl derivatives and methods of their use | COMT, MAOA, HTR3A | SLC6A2 63/4885SLC6A3 74/4885SLC6A4 41/4885 |
| US-20050143394-A1 | Phenylpiperazine cycloalkanol derivatives and methods of their use | HTR5A, PNMT, HTR3A | SLC6A2 49/4885SLC6A3 100/4885SLC6A4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.